144,506 members

Skip to content. | Skip to navigation

News

Annual review of The Branded Health Service Medicines (Costs) Regulations 2018

 

Start sharing

If you've got news you'd like to share, let us know and we'll consider it for our news section.
 

Annual review of The Branded Health Service Medicines (Costs) Regulations 2018

This review considers the extent to which the 2018 regulations have achieved their objectives, which are: to limit the growth in costs of branded health service medicines to safeguard the financial position of the NHS; to ensure medicines are available on reasonable terms, accounting for the costs of research and development; and to deliver the above objectives in a way consistent with supporting both the life sciences sector and broader economy.